Teri Foy

TERI FOY is an immunologist with more than twenty five years of biotechnology and pharmaceutical industry experience developing novel therapeutics in the areas of oncology and inflammation. At Bristol Myers Squibb, Foy leads the immuno-oncology and cell therapy thematic research center. Prior to her role at Bristol Myers Squibb, she worked at Celgene for more than five years. She was instrumental in establishing Celgene’s Seattle site, focusing initially on building the I-O strategy and pipeline, and subsequently expanding focus to include oversight of Celgene’s cell therapy research and early development strategy and pipeline. Earlier in her career, she held Seattle-based scientific leadership positions at Corixa Corp. and GlaxoSmithKline. She has an extensive publication record and holds nearly a dozen patents for novel immune compositions. Foy earned her doctorate in immunology from the University of Iowa, a master’s in microbiology, and completed her post-doctoral fellowship in immunology at Dartmouth Medical School. @bmsnews